SCHEMBL26212992

SCHEMBL26212992

O=S(=O)(NCCCl)c1ccc(CC2CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.46
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
PPARG P37231 1/20 0.41
CYP19A1 P11511 1/20 0.41
TBXA2R P21731 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26212901 0.78 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL4768496 0.76 HTR2C (0.52) GBA1ALDH1A1MEN1KMT2AHPGD
SCHEMBL23145309 0.75 MEN1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2CA1
SCHEMBL7023027 0.75 TSHR (0.64) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL26212915 0.75 LMNA (0.52) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL26212908 0.74 ALDH1A1 (0.69) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL1504601 0.74 ALDH1A1 (0.66) GBA1ALDH1A1MEN1KMT2AHPGD
SCHEMBL4182181 0.74 CYP3A4 (0.70) CA1CA2CA12CA6CA5A
SCHEMBL20522284 0.74 ALDH1A1 (0.70) ALDH1A1MEN1KMT2ASMN1; SMN2CA1
SCHEMBL8881270 0.73 ALDH1A1 (0.68) GBA1ALDH1A1KMT2ASMN1; SMN2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 GBA1 4497/4885ALDH1A1 995/4885MEN1 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.